These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 29566909)

  • 1. NAFLD, Helicobacter species and the intestinal microbiome.
    Castaño-Rodríguez N; Mitchell HM; Kaakoush NO
    Best Pract Res Clin Gastroenterol; 2017 Dec; 31(6):657-668. PubMed ID: 29566909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intestinal hormones, gut microbiota and non-alcoholic fatty liver disease.
    Koukias N; Buzzetti E; Tsochatzis EA
    Minerva Endocrinol; 2017 Jun; 42(2):184-194. PubMed ID: 27879962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Helicobacter pylori and non-alcoholic fatty liver disease: A new enigma?
    Abdel-Razik A; Mousa N; Shabana W; Refaey M; Elhelaly R; Elzehery R; Abdelsalam M; Elgamal A; Nassar MR; Abu El-Soud A; Seif AS; Tawfik AM; El-Wakeel N; Eldars W
    Helicobacter; 2018 Dec; 23(6):e12537. PubMed ID: 30246507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microbiota, Obesity and NAFLD.
    Lau LHS; Wong SH
    Adv Exp Med Biol; 2018; 1061():111-125. PubMed ID: 29956210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.
    Han R; Ma J; Li H
    Front Med; 2018 Dec; 12(6):645-657. PubMed ID: 30178233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Microbiome & NASH - partners in crime driving progression of fatty liver disease].
    Wree A; Geisler LJ; Tacke F
    Z Gastroenterol; 2019 Jul; 57(7):871-882. PubMed ID: 31288283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the gut microbiota in NAFLD.
    Leung C; Rivera L; Furness JB; Angus PW
    Nat Rev Gastroenterol Hepatol; 2016 Jul; 13(7):412-25. PubMed ID: 27273168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the Gut Microbiota for the Treatment of Non-Alcoholic Fatty Liver Disease.
    Mouzaki M; Bandsma R
    Curr Drug Targets; 2015; 16(12):1324-31. PubMed ID: 25882223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
    Xie C; Halegoua-DeMarzio D
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Influence of Gut Microbial Metabolism on the Development and Progression of Non-alcoholic Fatty Liver Disease.
    Jia W; Rajani C
    Adv Exp Med Biol; 2018; 1061():95-110. PubMed ID: 29956209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD.
    Pierantonelli I; Rychlicki C; Agostinelli L; Giordano DM; Gaggini M; Fraumene C; Saponaro C; Manghina V; Sartini L; Mingarelli E; Pinto C; Buzzigoli E; Trozzi L; Giordano A; Marzioni M; Minicis S; Uzzau S; Cinti S; Gastaldelli A; Svegliati-Baroni G
    Sci Rep; 2017 Sep; 7(1):12200. PubMed ID: 28939830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease.
    Aragonès G; González-García S; Aguilar C; Richart C; Auguet T
    Biomed Res Int; 2019; 2019():8507583. PubMed ID: 30719448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications.
    Chen J; Vitetta L
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32717871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.
    Hu H; Lin A; Kong M; Yao X; Yin M; Xia H; Ma J; Liu H
    J Gastroenterol; 2020 Feb; 55(2):142-158. PubMed ID: 31845054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut microbiota and non-alcoholic fatty liver disease.
    Gkolfakis P; Dimitriadis G; Triantafyllou K
    Hepatobiliary Pancreat Dis Int; 2015 Dec; 14(6):572-81. PubMed ID: 26663004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.
    Kirpich IA; Marsano LS; McClain CJ
    Clin Biochem; 2015 Sep; 48(13-14):923-30. PubMed ID: 26151226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease.
    Chu H; Duan Y; Yang L; Schnabl B
    Gut; 2019 Feb; 68(2):359-370. PubMed ID: 30171065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD).
    Buzzetti E; Pinzani M; Tsochatzis EA
    Metabolism; 2016 Aug; 65(8):1038-48. PubMed ID: 26823198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Helicobacter pylori infection is not associated with fatty liver disease including non-alcoholic fatty liver disease: a large-scale cross-sectional study in Japan.
    Okushin K; Takahashi Y; Yamamichi N; Shimamoto T; Enooku K; Fujinaga H; Tsutsumi T; Shintani Y; Sakaguchi Y; Ono S; Kodashima S; Fujishiro M; Moriya K; Yotsuyanagi H; Mitsushima T; Koike K
    BMC Gastroenterol; 2015 Feb; 15():25. PubMed ID: 25880912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.